High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study
Background: The current cure rates with triple therapy combining a proton-pump inhibitor, amoxicillin and clarithromycin are unacceptably low. Aims: To evaluate the efficacy of a 14-day concomitant therapy as an empirical first-line treatment for curing Helicobacter pylori (Hp) infection in primary...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464342/ https://www.ncbi.nlm.nih.gov/pubmed/32731455 http://dx.doi.org/10.3390/jcm9082410 |
_version_ | 1783577342655856640 |
---|---|
author | Olmedo, Llum Azagra, Rafael Aguyé, Amada Pascual, Marta Calvet, Xavier Gené, Emili |
author_facet | Olmedo, Llum Azagra, Rafael Aguyé, Amada Pascual, Marta Calvet, Xavier Gené, Emili |
author_sort | Olmedo, Llum |
collection | PubMed |
description | Background: The current cure rates with triple therapy combining a proton-pump inhibitor, amoxicillin and clarithromycin are unacceptably low. Aims: To evaluate the efficacy of a 14-day concomitant therapy as an empirical first-line treatment for curing Helicobacter pylori (Hp) infection in primary care. Methods: Patients from six primary care centers in Catalonia -Spain- were included consecutively. Hp status pre and post treatment was assessed according to local clinical practice protocol. A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs administered twice daily) was prescribed. Adherence to therapy and adverse events were assessed by personal interview. Results: 112 patients were enrolled. Mean age was 46.7 ± 16.1 years. Main indication for treatment was non-investigated dyspepsia (83%). Hp eradication was achieved in 100 of the 112 patients. Eradication rates were 89.3% (95% CI: 81.7–94.1) by intention-to-treat (ITT) analysis and 91.7% (95% CI; 84.6–95.9) per protocol (PP). No major side effects were reported; 104 (92.8%) patients complete the treatment. Forty-seven patients (42%) complained of mild side effects (metallic taste, nausea). Low adherence to treatment (p = 0.004) and significant adverse events (p = 0.004) were the variables associated with treatment failure. Conclusions: In primary care, a 14-day concomitant therapy is highly effective and well tolerated. |
format | Online Article Text |
id | pubmed-7464342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74643422020-09-04 High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study Olmedo, Llum Azagra, Rafael Aguyé, Amada Pascual, Marta Calvet, Xavier Gené, Emili J Clin Med Article Background: The current cure rates with triple therapy combining a proton-pump inhibitor, amoxicillin and clarithromycin are unacceptably low. Aims: To evaluate the efficacy of a 14-day concomitant therapy as an empirical first-line treatment for curing Helicobacter pylori (Hp) infection in primary care. Methods: Patients from six primary care centers in Catalonia -Spain- were included consecutively. Hp status pre and post treatment was assessed according to local clinical practice protocol. A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs administered twice daily) was prescribed. Adherence to therapy and adverse events were assessed by personal interview. Results: 112 patients were enrolled. Mean age was 46.7 ± 16.1 years. Main indication for treatment was non-investigated dyspepsia (83%). Hp eradication was achieved in 100 of the 112 patients. Eradication rates were 89.3% (95% CI: 81.7–94.1) by intention-to-treat (ITT) analysis and 91.7% (95% CI; 84.6–95.9) per protocol (PP). No major side effects were reported; 104 (92.8%) patients complete the treatment. Forty-seven patients (42%) complained of mild side effects (metallic taste, nausea). Low adherence to treatment (p = 0.004) and significant adverse events (p = 0.004) were the variables associated with treatment failure. Conclusions: In primary care, a 14-day concomitant therapy is highly effective and well tolerated. MDPI 2020-07-28 /pmc/articles/PMC7464342/ /pubmed/32731455 http://dx.doi.org/10.3390/jcm9082410 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Olmedo, Llum Azagra, Rafael Aguyé, Amada Pascual, Marta Calvet, Xavier Gené, Emili High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title | High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title_full | High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title_fullStr | High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title_full_unstemmed | High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title_short | High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study |
title_sort | high effectiveness of a 14-day concomitant therapy for helicobacter pylori treatment in primary care. an observational multicenter study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464342/ https://www.ncbi.nlm.nih.gov/pubmed/32731455 http://dx.doi.org/10.3390/jcm9082410 |
work_keys_str_mv | AT olmedollum higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy AT azagrarafael higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy AT aguyeamada higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy AT pascualmarta higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy AT calvetxavier higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy AT geneemili higheffectivenessofa14dayconcomitanttherapyforhelicobacterpyloritreatmentinprimarycareanobservationalmulticenterstudy |